Sentiment Trading

REGENXBIO Inc. has made significant progress in its gene therapy pipeline, with several promising therapies in development and a potential BLA submission for Duchenne muscular dystrophy treatment by mid-2026.

REGENXBIO Inc. is set to participate in several investor conferences in May 2025, showcasing its innovative pipeline and gene therapy innovations, and positioning itself for growth in the rapidly evolving biotechnology sector.